Literature DB >> 28759666

Association of Genetic Predisposition With Solitary Schwannoma or Meningioma in Children and Young Adults.

Omar N Pathmanaban1,2, Katherine V Sadler3,4, Ian D Kamaly-Asl2,5, Andrew T King1, Scott A Rutherford1, Charlotte Hammerbeck-Ward1, Martin G McCabe2,5, John-Paul Kilday2,5, Christian Beetz6, Nicola K Poplawski7, D Gareth Evans3,4, Miriam J Smith3,4.   

Abstract

Importance: Meningiomas and schwannomas are usually sporadic, isolated tumors occurring in adults older than 60 years and are rare in children and young adults. Multiple schwannomas and/or meningiomas are more frequently associated with a tumor suppressor syndrome and, accordingly, trigger genetic testing, whereas solitary tumors do not. Nevertheless, apparently sporadic tumors in young patients may herald a genetic syndrome. Objective: To determine the frequency of the known heritable meningioma- or schwannoma-predisposing mutations in children and young adults presenting with a solitary meningioma or schwannoma. Design, Setting, and Participants: Using the database of the Manchester Centre for Genomic Medicine, this cohort study analyzed lymphocyte DNA from young individuals prospectively referred to the clinic for genetic testing between January 1, 1990, and December 31, 2016, on presentation with a single meningioma (n = 42) or schwannoma (n = 135) before age 25 years. Sequencing data were also examined from an additional 39 patients with neurofibromatosis type 2 who were retrospectively identified as having a solitary tumor before age 25 years. Patients with schwannoma were screened for NF2, SMARCB1, and LZTR1 gene mutations, while patients with meningioma were screened for NF2, SMARCB1, SMARCE1, and SUFU. Main Outcomes and Measures: The type of underlying genetic mutation, or lack of a predisposing mutation, was associated with the presenting tumor type and subsequent development of additional tumors or other features of known schwannoma- and meningioma-predisposing syndromes.
Results: In 2 cohorts of patients who presented with an isolated meningioma (n = 42; median [range] age, 11 [1-24] years; 22 female) or schwannoma (n = 135; median [range] age, 18 [0.2-24] years; 60 female) before age 25 years, 16 of 42 patients (38%) had a predisposing mutation to meningioma and 27 of 135 patients (20%) to schwannoma, respectively. In the solitary meningioma cohort, 34 of 63 patients (54%) had a constitutional mutation in a known meningioma predisposition gene. Twenty-five of 63 patients (40%) had a constitutional NF2 mutation, and 9 (14%) had a constitutional SMARCE1 mutation. In the cohort of those who developed a solitary schwannoma before age 25 years, 44 of 153 patients (29%) had an identifiable genetic predisposition. Twenty-four patients (55%) with a spinal schwannoma had a constitutional mutation, while only 20 (18%) with a cranial schwannoma had a constitutional predisposition (P < .001). Of 109 cranial schwannomas, 106 (97.2%) were vestibular. Four of 106 people (3.8%) with a cranial schwannoma had an LZTR1 mutation (3 were vestibular schwannomas and 1 was a nonvestibular schwannoma), and 9 (8.5%) had an NF2 mutation. Conclusions and Relevance: A significant proportion of young people with an apparently sporadic solitary meningioma or schwannoma had a causative predisposition mutation. This finding has important clinical implications because of the risk of additional tumors and the possibility of familial disease. Young patients presenting with a solitary meningioma or schwannoma should be referred for genetic testing.

Entities:  

Mesh:

Year:  2017        PMID: 28759666      PMCID: PMC5710179          DOI: 10.1001/jamaneurol.2017.1406

Source DB:  PubMed          Journal:  JAMA Neurol        ISSN: 2168-6149            Impact factor:   18.302


  18 in total

1.  Evaluation of clinical diagnostic criteria for neurofibromatosis 2.

Authors:  M E Baser; J M Friedman; A J Wallace; R T Ramsden; H Joe; D G R Evans
Journal:  Neurology       Date:  2002-12-10       Impact factor: 9.910

2.  Germline mutations in SUFU cause Gorlin syndrome-associated childhood medulloblastoma and redefine the risk associated with PTCH1 mutations.

Authors:  Miriam J Smith; Christian Beetz; Simon G Williams; Sanjeev S Bhaskar; James O'Sullivan; Beverley Anderson; Sarah B Daly; Jill E Urquhart; Zaynab Bholah; Deemesh Oudit; Edmund Cheesman; Anna Kelsey; Martin G McCabe; William G Newman; D Gareth R Evans
Journal:  J Clin Oncol       Date:  2014-11-17       Impact factor: 44.544

3.  Germline SMARCB1 mutation and somatic NF2 mutations in familial multiple meningiomas.

Authors:  I Christiaans; S B Kenter; H C Brink; T A M van Os; F Baas; P van den Munckhof; A M J Kidd; T J M Hulsebos
Journal:  J Med Genet       Date:  2010-10-07       Impact factor: 6.318

4.  Mosaicism in neurofibromatosis type 2: an update of risk based on uni/bilaterality of vestibular schwannoma at presentation and sensitive mutation analysis including multiple ligation-dependent probe amplification.

Authors:  D Gareth R Evans; R T Ramsden; A Shenton; C Gokhale; N L Bowers; S M Huson; G Pichert; A Wallace
Journal:  J Med Genet       Date:  2007-02-16       Impact factor: 6.318

5.  Aggressive phenotypic and genotypic features in pediatric and NF2-associated meningiomas: a clinicopathologic study of 53 cases.

Authors:  A Perry; C Giannini; R Raghavan; B W Scheithauer; R Banerjee; L Margraf; D C Bowers; R A Lytle; I F Newsham; D H Gutmann
Journal:  J Neuropathol Exp Neurol       Date:  2001-10       Impact factor: 3.685

6.  A clinical study of type 2 neurofibromatosis.

Authors:  D G Evans; S M Huson; D Donnai; W Neary; V Blair; V Newton; R Harris
Journal:  Q J Med       Date:  1992-08

Review 7.  Intracranial meningiomas in children: report of 27 new cases and critical analysis of 440 cases reported in the literature.

Authors:  Emanuela Caroli; Michelangelo Russillo; Luigi Ferrante
Journal:  J Child Neurol       Date:  2006-01       Impact factor: 1.987

8.  Proteomic and bioinformatic analysis of mammalian SWI/SNF complexes identifies extensive roles in human malignancy.

Authors:  Cigall Kadoch; Diana C Hargreaves; Courtney Hodges; Laura Elias; Lena Ho; Jeff Ranish; Gerald R Crabtree
Journal:  Nat Genet       Date:  2013-05-05       Impact factor: 38.330

9.  Revisiting neurofibromatosis type 2 diagnostic criteria to exclude LZTR1-related schwannomatosis.

Authors:  Miriam J Smith; Naomi L Bowers; Michael Bulman; Carolyn Gokhale; Andrew J Wallace; Andrew T King; Simon K L Lloyd; Scott A Rutherford; Charlotte L Hammerbeck-Ward; Simon R Freeman; D Gareth Evans
Journal:  Neurology       Date:  2016-11-16       Impact factor: 9.910

10.  Germline SMARCE1 mutations predispose to both spinal and cranial clear cell meningiomas.

Authors:  Miriam J Smith; Andrew J Wallace; Chris Bennett; Martin Hasselblatt; Ewelina Elert-Dobkowska; Linton T Evans; William F Hickey; Jack van Hoff; David Bauer; Amy Lee; Robert F Hevner; Christian Beetz; Daniel du Plessis; John-Paul Kilday; William G Newman; D Gareth Evans
Journal:  J Pathol       Date:  2014-10-06       Impact factor: 7.996

View more
  14 in total

1.  [Persistent chest pain for 4 months and progressive lower limb weakness for 2 months in a boy].

Authors:  Hong-Ling Wei; Shan Lu; Yan-Mei Chang
Journal:  Zhongguo Dang Dai Er Ke Za Zhi       Date:  2019-08

Review 2.  Beyond Antoni: A Surgeon's Guide to the Vestibular Schwannoma Microenvironment.

Authors:  Cathal J Hannan; Daniel Lewis; Claire O'Leary; Carmine A Donofrio; Dafydd G Evans; Emma Stapleton; Simon R Freeman; Simon K Lloyd; Scott A Rutherford; Charlotte Hammerbeck-Ward; David Brough; Stuart M Allan; David Coope; Andrew T King; Omar N Pathmanaban
Journal:  J Neurol Surg B Skull Base       Date:  2020-09-10

3.  EANO guideline on the diagnosis and treatment of vestibular schwannoma.

Authors:  Roland Goldbrunner; Michael Weller; Jean Regis; Morten Lund-Johansen; Pantelis Stavrinou; David Reuss; D Gareth Evans; Florence Lefranc; Kita Sallabanda; Andrea Falini; Patrick Axon; Olivier Sterkers; Laura Fariselli; Wolfgang Wick; Joerg-Christian Tonn
Journal:  Neuro Oncol       Date:  2020-01-11       Impact factor: 12.300

4.  Neurofibromatosis type 2 initially presenting as a preauricular mass: a case report.

Authors:  Wei-Che Lan; Yu Aoh; Rui-Yun Chen; Hui-Chi Tien; Chia-Der Lin
Journal:  J Otolaryngol Head Neck Surg       Date:  2020-06-26

Review 5.  Familial Syndromes Involving Meningiomas Provide Mechanistic Insight Into Sporadic Disease.

Authors:  Keith Kerr; Krista Qualmann; Yoshua Esquenazi; John Hagan; Dong H Kim
Journal:  Neurosurgery       Date:  2018-12-01       Impact factor: 4.654

6.  Familial unilateral vestibular schwannoma is rarely caused by inherited variants in the NF2 gene.

Authors:  D Gareth Evans; Andrew J Wallace; Claire Hartley; Simon R Freeman; Simon K Lloyd; Owen Thomas; Patrick Axon; Charlotte L Hammerbeck-Ward; Omar Pathmanaban; Scott A Rutherford; Mark Kellett; Roger Laitt; Andrew T King; Jemma Bischetsrieder; Jaishri Blakeley; Miriam J Smith
Journal:  Laryngoscope       Date:  2018-10-16       Impact factor: 3.325

7.  Optical coherence tomography significance in managing complex neurofibromatosis 2-related papilledema: Report of a case.

Authors:  Giacomo Maria Bacci; Flavio Giordano; Iacopo Sardi; Gareth Evans; Omar Pathmanaban; Carla Fonte; Franco Trabalzini; Sergio Nappini; Regina Mura; Roberto Caputo
Journal:  JRSM Open       Date:  2021-01-11

8.  Whole Genome Sequencing Identifies Key Genes in Spinal Schwannoma.

Authors:  Xin Gao; Li Zhang; Qi Jia; Liang Tang; Wen Guo; Tao Wang; Zheyu Wu; Wang Zhou; Zhenxi Li; Jianru Xiao
Journal:  Front Genet       Date:  2020-10-30       Impact factor: 4.599

Review 9.  Neurofibromatosis in Children: Actually and Perspectives.

Authors:  Maria Lucia Sur; Ionel Armat; Genel Sur; Diana-Cristina Pop; Gabriel Samasca; Iulia Lupan; Teodora-Larisa Timis; Ioan-Alexandru Florian; Daniel Sur
Journal:  Children (Basel)       Date:  2022-01-02

10.  Current recommendations for clinical surveillance and genetic testing in rhabdoid tumor predisposition: a report from the SIOPE Host Genome Working Group.

Authors:  M C Frühwald; K Nemes; H Boztug; M C A Cornips; D G Evans; R Farah; S Glentis; M Jorgensen; K Katsibardi; S Hirsch; K Jahnukainen; I Kventsel; K Kerl; C P Kratz; K W Pajtler; U Kordes; V Ridola; E Stutz; F Bourdeaut
Journal:  Fam Cancer       Date:  2021-02-03       Impact factor: 2.375

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.